ITCI Stock Quote Price and Forecast | CNN

ITCI

Intra-Cellular Therapies, Inc.

Key terms

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Today 3:45pm ET Intra-Cellular Therapies: Hold Rating with Increased Price Target Amid Caplyta’s Clinical Success by TipRanks Today 8:11am ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI) by TipRanks Today 7:22am ET Intra-Cellular Advances Depression Treatment with Lumateperone by TipRanks Apr 05 8:14am ET Needham remains positive on Intra-Cellular ahead of Caplyta readouts by TipRanks Apr 05 7:00am ET Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI) by TipRanks Apr 05 5:25am ET Intra-Cellular Therapies Buy Rating: High Confidence in Caplyta’s Success for MDD Treatment by TipRanks Apr 03 7:00am ET Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI) by TipRanks Apr 03 1:46am ET Intra-Cellular Therapies: A Strong Buy on Patent Defense and Promising Clinical Prospects by TipRanks Mar 21 2:45am ET Buy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership Enhancements by TipRanks Mar 19 9:02am ET Intra-Cellular Therapies Announces Executive Leadership Changes by TipRanks Mar 19 8:33am ET Intra-Cellular promotes Halstead to President, CFO Hineline to retire by TipRanks Mar 05 1:26am ET Buy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta’s MDD Trial by TipRanks Mar 01 1:13am ET Outperform Rating for Intra-Cellular Therapies Amidst Strong Caplyta Sales and Promising Clinical Prospects by TipRanks Feb 25 11:56pm ET Optimistic Buy Rating for Intra-Cellular Therapies Amid Growth and Operational Efficiency by TipRanks Feb 25 11:25pm ET Intra-Cellular Therapies: Sustained Growth and Buy Opportunity Amid Caplyta’s Progress by TipRanks Feb 23 11:55am ET JPMorgan biotech analysts to hold an analyst/industry conference call by TipRanks Feb 23 11:00am ET JPMorgan biotech analysts to hold an analyst/industry conference call by TipRanks Feb 23 8:25am ET Intra-Cellular Therapies: A Strong Buy on Robust Sales Growth and Promising Trial Prospects by TipRanks Feb 23 8:07am ET Intra-Cellular price target raised to $82 from $72 at Needham by TipRanks Feb 23 7:37am ET Intra-Cellular Therapies: A Buy Rating Reinforced by Caplyta’s Performance and Promising Pipeline by TipRanks Feb 23 7:20am ET Intra-Cellular price target lowered to $100 from $101 at Canaccord by TipRanks Feb 23 7:19am ET RBC Capital Gives a Buy Rating to Intra-Cellular Therapies (ITCI) by TipRanks Feb 23 6:10am ET Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Penumbra (PEN) and BioMarin Pharmaceutical (BMRN) by TipRanks Feb 23 5:16am ET Optimistic Outlook for Intra-Cellular Therapies: A Strong Buy Rating Backed by Caplyta’s Revenue Growth and Pipeline Potential by TipRanks Feb 22 2:50pm ET Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI) by TipRanks Feb 22 1:45pm ET Buy Rating Affirmed for Intra-Cellular Therapies on Strong Caplyta Sales and Promising Clinical Trials by TipRanks Feb 22 7:53am ET Intra-Cellular Therapies Business and Clinical Progress Update by TipRanks Feb 22 7:38am ET Intra-Cellular reports Q4 EPS (30c), consensus (44c) by TipRanks Feb 21 8:25pm ET Notable companies reporting before tomorrow’s open by TipRanks Feb 21 2:20pm ET Notable companies reporting before tomorrow’s open by TipRanks Feb 15 6:47am ET Intra-Cellular price target raised to $82 from $76 at Mizuho by TipRanks

No recent press releases are available for ITCI

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.

Scott Olson/Getty Images

Trump’s stock tumbles again after Truth Social announces it’s getting into streaming

Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images

Samuel Corum/Bloomberg/Getty Images

Geopolitical strife is roiling Wall Street. Here’s what investors are watching

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments